Anticoagulation for heparin-induced thrombocytopenia before, during, and after peripheral endovascular procedures
Review published in Vasa (2025)
Abstract
Acute heparin-induced thrombocytopenia (HIT) type II requires the immediate discontinuation of heparin and initiation of a non-heparin anticoagulant. Lifelong avoidance of heparin is generally recommended due to the risk of recurrence. Therefore, anticoagulation management in endovascular procedures remains challenging, as heparin is the preferred anticoagulant and evidence on alternative strategies is limited. This narrative review outlines an institutional approach aligned with current guidelines and examines the available data on non-heparin anticoagulants in this setting. Current evidence may support the use of bivalirudin among non-heparin anticoagulants for peripheral endovascular interventions due to indirect evidence of its use during percutaneous coronary intervention in patients with acute HIT. However, bivalirudin is often not available due to drug shortage and not approved for HIT in Europe. This leaves argatroban as the main alternative, particularly in patients with renal impairment. Data on non-heparin anticoagulation for HIT were extrapolated from other types of intervention and from small retrospective studies. In selected cases of patients with remote or subacute HIT B and negative antibodies, intraoperative heparin may be considered if alternative anticoagulants are not practical, particularly in emergency situations, even in this approach is controversial and not discussed in current guidelines regarding peripheral endovascular procedures. In the absence of robust evidence, anticoagulation strategies should be individualized and patients adequately informed. Further studies are necessary to optimize anticoagulant management among patients with HIT undergoing peripheral endovascular interventions.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
This narrative review outlines an institutional approach to anticoagulation for peripheral endovascular procedures in patients with heparin-induced thrombocytopenia, finding indirect evidence supporting bivalirudin and identifying argatroban as the main alternative, particularly in renal impairment, given bivalirudin's frequent unavailability and lack of European approval for HIT.
Why This Matters for Hirudotherapy
This review outlined an institutional approach to anticoagulation management for patients with heparin-induced thrombocytopenia undergoing peripheral endovascular procedures, examining non-heparin alternatives including bivalirudin and argatroban. The abstract notes that bivalirudin received indirect support from PCI literature but faces availability limitations and lacks HIT approval in Europe, leaving argatroban as the main alternative, particularly in renal impairment. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.
Citation
Reference (Vancouver style)
Cardi S, Trinchero A, Studt JD, Fumagalli RM, Kucher N, Barco S. Anticoagulation for heparin-induced thrombocytopenia before, during, and after peripheral endovascular procedures. Vasa. 2026;55(1):18-29. doi:10.1024/0301-1526/a001220. PMID: 40778562
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026